The decision to administer recombinant erythropoietins should be based on a benefit-risk assessment with the participation of the individual patient, which should take into account the specific clinical context.
Rekombinantsete erütropoetiinide manustamise otsus peab põhinema iga patsiendi osalusel tehtud riski ja kasu suhte hinnangul, võttes arvesse spetsiifilist kliinilist tausta.